Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

NCT02535221 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

234

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Goserelin+TAM+AI
DRUG: Epirubicin+CTX+5-Fu

Sponsor

Peking University